|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||26.59 - 27.48|
|52 Week Range||16.50 - 39.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.40|
- Durability of clinical effect was seen across multiple outcome measures and findings were consistent across both pivotal Phase 3 trials. - A single dose of rimegepant, without any rescue medications, was superior to placebo for pain freedom and pain relief at 2 hours post-dosing, and showed a profile of increasing improvement throughout the first eight hours that was sustained compared to placebo out to 24 and 48 hours. - The vast majority of rimegepant treated patients did not take rescue medications during the 24 hour period after dosing.
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Data detailing single-dose durable headache relief and recovery of function endpoints from the two pivotal Phase 3 studies of rimegepant, Biohaven's oral CGRP receptor antagonist. - Leading migraine ...
NEW HAVEN, Conn. , April 5, 2018 /PRNewswire/ -- Kleo Pharmaceuticals, a biopharmaceutical company developing innovative small molecule immunotherapies, announced today that CEO Doug Manion , M.D. FRCP ...
NEW HAVEN, Conn., April 3, 2018 /PRNewswire/ -- Kleo Pharmaceuticals Inc., a biotechnology company pioneering a new class of immunotherapies utilizing small molecules to activate an individual's own immune system to fight against cancers and other diseases, announced today the appointment of Luca Rastelli PhD, as Chief Scientific Officer, effective immediately and reporting to Doug Manion, CEO. Dr. Rastelli will lead all aspects of R&D for the company and serve as the scientific external face of Kleo Pharmaceuticals to the investor, scientific, medical and patient communities. "We welcome Luca to the Kleo Pharmaceuticals executive team," said Kleo's Chief Executive Officer, Doug Manion, M.D., FRCP(C).
Stock Monitor: Cytori Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Biohaven Pharma Holding Co. Ltd. (NYSE: ...
Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) investors took their profits Monday after the firm reported positive Phase 3 data for rimegepant. One analyst considers the related sell-off an entry ...
The week is now well underway and there are a couple of major developments in the biotechnology space, both of which are related to the release of clinical trial data and both of which have translated to some real volatility in the market capitalization of the companies to which they relate. The two companies in […] The post Here’s What’s Moving AnaptysBio and Biohaven Pharmaceutical appeared first on Market Exclusive.
Biohaven fell more than 30% early Monday after it unveiled the results of two late-stage trials for its migraine drug.
Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan's rival treatment. In February, Allergan reported strong efficacy data for its migraine treatment, ubrogepant. A late entrant to the competitive arena of migraine treatments, Connecticut-based Biohaven's rimegepant is part of a new class of medicines called CGRP receptor antagonists.
Biohaven Pharmaceutical Holding Co. Ltd. shares dropped nearly 23% in premarket trade Monday after the company released data from two phase 3 clinical trials for its migraine drug rimegepant. The company ...
- Rimegepant met both registrational co-primary endpoints (pain freedom and freedom from most bothersome symptom at 2 hours) in two pivotal Phase 3 trials - Results are statistically significant and clinically ...
Biohaven Pharmaceutical Holding Company Ltd’s (NYSE:BHVN): Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The US$1.07B market-cap company announcedRead More...
Investors in Biohaven Pharmaceutical (BHVN) need to pay close attention to the stock based on moves in the options market lately.
NEW HAVEN, Conn., March 12, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company") announced today a restructuring of its global license agreement with Bristol-Myers Squibb Company (BMY) ("BMS") for Biohaven's small molecule calcitonin gene-related peptide (CGRP) receptor antagonist platform, which includes its product candidates rimegepant, a potentially best-in-class CGRP receptor antagonist for the acute treatment of migraine, and BHV-3500, a third-generation antagonist for the acute treatment and prevention of migraine. As part of the restructuring, Biohaven will pay BMS an upfront payment of $50 million in return for a low single digit reduction in the royalties payable on net sales of rimegepant and a mid-single digit reduction in the royalties payable on net sales of BHV-3500.
NEW HAVEN, Conn., March 6, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the fourth quarter and year ended December 31, 2017 and provided a review of recent accomplishments and anticipated upcoming milestones.
NEW HAVEN, Conn., March 6, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) announced today that it has enrolled the first patient in a Phase 3 clinical trial of the Zydis® orally dissolving tablet ("ODT") formulation of rimegepant for the acute treatment of migraine. Rimegepant is a potent, orally available small molecule calcitonin gene-related peptide ("CGRP") receptor antagonist in late stage development for the treatment of migraine. The Phase 3 clinical trial will assess the onset of action, patient satisfaction, efficacy and safety of the fast-dissolve Zydis® ODT formulation of rimegepant.
NEW HAVEN, Conn., March 1, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company") announced positive results today from its bioequivalence study with rimegepant Zydis® orally dissolving tablets (ODT). Rimegepant is a small molecule, oral, calcitonin gene-related peptide ("CGRP") receptor antagonist currently in two pivotal Phase 3 trials for the acute treatment of migraine using a tablet formulation. Biohaven has been working with Catalent U.K. Swindon Zydis Limited, a subsidiary of Catalent, Inc. (CTLT) ("Catalent") to develop a new ODT formulation of rimegepant which dissolves on the tongue without the need for fluid intake.
NEW HAVEN, Conn., Feb. 21, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company") announced today that it has entered into an exclusive worldwide license agreement with Catalent U.K. Swindon Zydis Limited, a subsidiary of Catalent, Inc. (CTLT) ("Catalent") to provide Catalent's Zydis® ODT (orally disintegrating tablet) fast-dissolving formulation for the development of Biohaven's lead calcitonin gene-related peptide (CGRP) receptor antagonist product candidate, rimegepant. The agreement also provides exclusive rights for developing small molecule CGRP receptor antagonists with the Zydis ODT technology.
NEW YORK, Feb. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Great ...
NEW YORK, Feb. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Park ...
BHV-5000 is a low trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist licensed to Biohaven from AstraZeneca. BHV-5000 was previously advanced into a Phase 1 clinical trial, as a drug in solution formulation, and the active metabolite of BHV-5000, lanicemine, was previously advanced through Phase 2 trials. Unlike other potent NMDA receptor targeting compounds, BHV-5000 is a NMDA antagonist that has not been associated with the prominent psychotomimetic effects.
LONDON, UK / ACCESSWIRE / January 11, 2018 / Active-Investors.com has just released a free research report on Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN ) ("Biohaven"). If you want access ...